FDA approves treatment for weight management in patients with Bardet-Biedl Syndrome aged 6 or older

[FDA]

The U.S. Food and Drug Administration has approved a supplemental indication for Imcivree (setmelanotide) injection for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl Syndrome (BBS). Imcivree is the first drug approved specifically


Baca selengkapnya di : http://www.fda.gov...